NO994508L - Stabile partikler i flytende formuleringer - Google Patents

Stabile partikler i flytende formuleringer

Info

Publication number
NO994508L
NO994508L NO994508A NO994508A NO994508L NO 994508 L NO994508 L NO 994508L NO 994508 A NO994508 A NO 994508A NO 994508 A NO994508 A NO 994508A NO 994508 L NO994508 L NO 994508L
Authority
NO
Norway
Prior art keywords
microparticles
sugar glass
liquid formulations
mannitol
stable particles
Prior art date
Application number
NO994508A
Other languages
English (en)
Norwegian (no)
Other versions
NO994508D0 (no
Inventor
Jaap Kampinga
Original Assignee
Quadrant Holdings Cambridge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10809442&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO994508(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Quadrant Holdings Cambridge filed Critical Quadrant Holdings Cambridge
Publication of NO994508D0 publication Critical patent/NO994508D0/no
Publication of NO994508L publication Critical patent/NO994508L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO994508A 1997-03-18 1999-09-17 Stabile partikler i flytende formuleringer NO994508L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9705588.3A GB9705588D0 (en) 1997-03-18 1997-03-18 Stable particle in liquid formulations
PCT/GB1998/000817 WO1998041188A2 (en) 1997-03-18 1998-03-18 Stable particle in liquid formulations

Publications (2)

Publication Number Publication Date
NO994508D0 NO994508D0 (no) 1999-09-17
NO994508L true NO994508L (no) 1999-11-17

Family

ID=10809442

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994508A NO994508L (no) 1997-03-18 1999-09-17 Stabile partikler i flytende formuleringer

Country Status (14)

Country Link
US (1) US6669963B1 (de)
EP (1) EP1007000B1 (de)
JP (1) JP2002504090A (de)
CN (1) CN1256626A (de)
AT (1) ATE325605T1 (de)
AU (1) AU722627B2 (de)
BR (1) BR9808920A (de)
CA (1) CA2293682C (de)
DE (1) DE69834495T2 (de)
EA (1) EA001873B1 (de)
GB (1) GB9705588D0 (de)
NO (1) NO994508L (de)
NZ (1) NZ337666A (de)
WO (1) WO1998041188A2 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ88697A3 (en) 1994-09-22 1997-09-17 Quadrant Holdings Cambridge Composition used for re-hydration and nourishment in the course of athletic outputs and processes for preparing thereof
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
EP1071465A1 (de) * 1998-03-18 2001-01-31 Ronai, Peter Amorphe gläser zur stabilisierung von empfindlichen produkten
US6190701B1 (en) 1999-03-17 2001-02-20 Peter M. Ronai Composition and method for stable injectable liquids
US6102896A (en) * 1999-09-08 2000-08-15 Cambridge Biostability Limited Disposable injector device
DE19943491B4 (de) * 1999-09-10 2010-04-01 Südzucker AG Mannheim/Ochsenfurt Verbesserte Komprimate
WO2001037804A2 (en) * 1999-11-22 2001-05-31 Universal Preservation Technologies, Inc. Preservation and formulation of bioactive materials
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
GB0024271D0 (en) * 2000-09-25 2000-11-15 Colaco Camilo Improved methods and compositions for pulmonary delivery of actives
RU2259817C2 (ru) * 2000-10-13 2005-09-10 Кембридж Байостэбилити Лтд. Композиция для доставки стабильных инъецируемых жидкостей и способ доставки
DE60043459D1 (de) * 2000-10-13 2010-01-14 Cambridge Biostability Ltd Pharmazeutische flüssige Suspensionen
ES2337252T3 (es) * 2000-10-13 2010-04-22 Nova Bio-Pharma Technologies Limited Suspensiones liquidas farmaceuticas.
WO2002032398A2 (en) * 2000-10-16 2002-04-25 Massachusetts Institute Of Technology Lipid-protein-sugar particles for drug delivery
US7153472B1 (en) 2000-11-22 2006-12-26 Quadrant Drug Delivery Limited Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
US6623762B2 (en) * 2001-02-16 2003-09-23 Cambridge Biostability Ltd. Composition and method for controlled release injections
FR2825276B1 (fr) * 2001-05-31 2004-11-26 Seppic Sa Adujvant d'immunite sous forme solide et vaccin le contenant
US20040197885A1 (en) * 2001-07-02 2004-10-07 Shigeru Ueda Method of stabilizing alkaline phosphatase
WO2003016325A1 (en) * 2001-08-10 2003-02-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Association compound of trehalose or maltitol with metal ion compound
GB2404865B (en) 2001-09-11 2005-09-28 Caretek Medical Ltd Novel drug delivery technology
ES2364636T3 (es) 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
AU2004285448C1 (en) * 2003-10-23 2021-08-19 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
FR2873386B1 (fr) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa Composition vaccinale contre le rhodococcus equi
US20060045891A1 (en) * 2004-08-24 2006-03-02 Lovalenti Phillip M Density-matched suspension vehicles and pharmaceutical suspensions
US20060142630A1 (en) * 2004-12-29 2006-06-29 Attila Meretei Systems and methods for treating a thrombus in a blood vessel
US7515971B1 (en) * 2005-09-09 2009-04-07 Pacesetter, Inc. Left atrial pressure sensor lead
GB2430880A (en) * 2005-10-04 2007-04-11 Cambridge Biostability Ltd Pharmaceutical compositions stabilized in glassy particles
GB0523638D0 (en) 2005-11-21 2005-12-28 Cambridge Biostability Ltd Pharmaceutical device for the administration of substances to patients
US8946200B2 (en) 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
DE102006056790B3 (de) * 2006-12-01 2008-01-17 IfP Privates Institut für Produktqualität GmbH Laboreinmalartikel für Analyse und Diagnosik
EP1930396B1 (de) * 2006-12-04 2011-07-06 Merck Patent GmbH Furochromanderivate
US20090022727A1 (en) 2007-01-26 2009-01-22 Alza Corp. Injectable, nonaqueous suspension with high concentration of therapeutic agent
JP4879349B2 (ja) * 2007-07-31 2012-02-22 大塚製薬株式会社 アリピプラゾール懸濁液及び凍結乾燥製剤の製造方法
MX2010009351A (es) * 2008-02-25 2011-03-04 Novavax Inc Particulas similares a virus cristalizadas con azucar.
US8404850B2 (en) 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
US8722706B2 (en) 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en) 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
WO2011007327A2 (en) * 2009-07-16 2011-01-20 Koninklijke Philips Electronics N.V. Suspension for therapeutic use and device for delivering said suspension
US8293299B2 (en) 2009-09-11 2012-10-23 Kraft Foods Global Brands Llc Containers and methods for dispensing multiple doses of a concentrated liquid, and shelf stable Concentrated liquids
CN102115737B (zh) * 2009-12-31 2015-06-03 深圳迈瑞生物医疗电子股份有限公司 稳定碱性磷酸酶或其标记物的试剂和方法
US9028873B2 (en) 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
CN102269762B (zh) 2010-06-04 2014-12-10 深圳迈瑞生物医疗电子股份有限公司 结合物的制备方法及相关试剂盒
CN102269761A (zh) 2010-06-04 2011-12-07 深圳迈瑞生物医疗电子股份有限公司 一种碱性磷酸酶结合物的合成工艺
US20120222979A1 (en) 2011-03-04 2012-09-06 Elwha LLC, a limited liability company of the State of Delaware Glassy compositions
EP2753185B1 (de) 2011-09-09 2018-08-01 Kraft Foods Group Brands LLC Lagerstabile, gebraute getränke-konzentrate und verfahren zu deren herstellung
SG10201604104PA (en) 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
US11013248B2 (en) 2012-05-25 2021-05-25 Kraft Foods Group Brands Llc Shelf stable, concentrated, liquid flavorings and methods of preparing beverages with the concentrated liquid flavorings
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
WO2016004285A1 (en) 2014-07-03 2016-01-07 Kraft Foods Group Brands Llc Low water coffee and tea beverage concentrates and methods for making the same
CN111558046A (zh) * 2020-05-27 2020-08-21 华润昂德生物药业有限公司 海藻糖在制备重组人促红素液体制剂中的应用及重组人促红素液体制剂、制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3970765A (en) * 1975-07-03 1976-07-20 General Foods Corporation Method for producing sucrose fixed volatile flavors
US4031255A (en) * 1975-07-03 1977-06-21 General Foods Corporation Fixing acetaldehyde in sucrose
GB1490814A (en) * 1975-07-22 1977-11-02 Cadbury Ltd Heat-resistant chocolate product and method of manufacturing same
JPS562908A (en) * 1979-06-20 1981-01-13 Nikken Kagaku Kk Preparation of stable live bacterial pharmaceutical remedy
DE3484584D1 (de) * 1983-10-14 1991-06-20 Sumitomo Pharma Injektionen mit verzoegerter abgabe.
WO1989003671A1 (fr) * 1987-10-29 1989-05-05 Dainippon Pharmaceutical Co., Ltd. Preparation a liberation entretenue
US5250429A (en) * 1991-09-20 1993-10-05 Pharmacia P-L Biochemicals Inc. Glassified restriction enzymes
US5424289A (en) * 1993-07-30 1995-06-13 Alza Corporation Solid formulations of therapeutic proteins for gastrointestinal delivery
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
CA2197982C (en) * 1994-08-04 2010-03-23 Bruce Joseph Roser Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US5593824A (en) * 1994-09-02 1997-01-14 Pharmacia Biotech, Inc. Biological reagent spheres
GB9508691D0 (en) * 1995-04-28 1995-06-14 Pafra Ltd Stable compositions
DE69628007T2 (de) 1995-06-07 2003-11-27 Elan Drug Delivery Ltd., Ruddington Verfahren zur stabilen einarbeitung von substanzen in trockene geschäumte glasmatrizen und auf diese weise hergestellte zusammensetzungen
US5958455A (en) 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
US5762961A (en) 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US5766520A (en) 1996-07-15 1998-06-16 Universal Preservation Technologies, Inc. Preservation by foam formation

Also Published As

Publication number Publication date
ATE325605T1 (de) 2006-06-15
DE69834495D1 (de) 2006-06-14
EP1007000B1 (de) 2006-05-10
NO994508D0 (no) 1999-09-17
EP1007000A2 (de) 2000-06-14
WO1998041188A2 (en) 1998-09-24
CN1256626A (zh) 2000-06-14
DE69834495T2 (de) 2006-09-07
WO1998041188A3 (en) 1998-12-10
CA2293682A1 (en) 1998-09-24
AU722627B2 (en) 2000-08-10
US6669963B1 (en) 2003-12-30
AU6510198A (en) 1998-10-12
GB9705588D0 (en) 1997-05-07
EA199900835A1 (ru) 2000-04-24
EA001873B1 (ru) 2001-10-22
NZ337666A (en) 2001-04-27
JP2002504090A (ja) 2002-02-05
BR9808920A (pt) 2000-08-01
CA2293682C (en) 2007-01-16

Similar Documents

Publication Publication Date Title
NO994508D0 (no) Stabile partikler i flytende formuleringer
IL96276A0 (en) Transdermal delivery system of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole
AU5936400A (en) Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
NZ336594A (en) Formulation for inhalation which includes a carrier (lactose, glucose, raffinose, melezitose, lactitol, trehalose, sucrose, mannitol or starch
CA2024291A1 (en) Dosage device and preparation and use thereof
TW224428B (de)
AU8050791A (en) Compositions and methods for the controlled release of soluble active substances
WO2002067902A3 (en) Modulation of release from dry powder formulations
NZ336593A (en) Formulation comprising finely divided formoterol and a carrier (lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol or starch
IT8720129A0 (it) Composizioni farmaceutiche sottoforma di sospensioni stabili di sucralfato esenti da agenti sospendenti.
MY113718A (en) Pharmaceutical formulation containing a hydrophobic active substance and an effervescent system, and process for the preparation of the formulation
NZ336595A (en) Formulation for inhalation comprising finely divided terbutaline sulphate and a carrier (lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol or starch)
EP1086933A3 (de) Zementzusammensetzung
MXPA03008061A (es) Composiciones desodorantes y antitranspirantes anhidras que contienen un agente dermoactivo solido soluble en agua y glicerina.
IN172858B (de)
EP0435632A3 (en) Phenylpyrimidine derivatives, process for preparing the same, liquid crystal compositions containing said derivatives as active ingredient, and liquid crystal elements using such compositions
NZ227700A (en) Liquid pharmaceutical compositions containing 4-aroylimidazol-2-ones and nonionic surfactants
MY103584A (en) 8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it
SG25394G (en) Sustained release pharmaceutical compositions and the preparation of particles for use therein.
Dupuis et al. Rheo-optical properties of polymer solutions
AR019776A1 (es) Implante aloplastico de microparticulas para medicina estetica y aplicacion del mismo
ATE154827T1 (de) Stabilisiertes gelsystem und dessen herstellung
WANG Components of cosmic background radiation and their interaction with matter(Ph. D. Thesis)
IL128537A0 (en) Compositions for the substained release of flurbiprofen or other hydrophobic drugs
IT8720225A0 (it) Composizioni cosmetiche contenenti come principio attivo adenosin monofosfato ciclico e fosfatidil inositolo o inositolo

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application